Fed. Circ. Backs Ban On Generic Treximet

Law360, New York (September 28, 2012, 8:21 PM EDT) -- The Federal Circuit on Friday upheld an injunction barring three generic-drug makers from offering their own versions of Pozen Inc.'s migraine treatment Treximet, rejecting arguments that the patents for the drug were invalid.

The appeals court said a Texas federal court had made no errors when it declared Pozen's patents legitimate last year, meaning Par Pharmaceutical Cos., Alphapharm Pty Ltd. and Dr. Reddy’s Laboratories Ltd. are still banned from selling their generic versions.

Treximet, created by Pozen in collaboration with GlaxoSmithKline PLC, is a combination of...
To view the full article, register now.